

The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp¹³) encapsulated in cationic liposome

Author(s): Jaafari, MR (Jaafari, Mahmoud R.); Badiee, A (Badiee, Ali); Khamesipour, A (Khamesipour, Ali); Samiei, A (Samiei, Afshin); Soroush, D (Soroush, Dina); Kheiri, MT (Kheiri, Masoumeh Tavassoti); Barkhordari, F (Barkhordari, Farzaneh); McMaster, WR (McMaster, W. Robert); Mahboudi, F (Mahboudi, Fereidoun)

Source: VACCINE **Volume:** 25 **Issue:** 32 **Pages:** 6107-6114 **DOI:** 10.1016/j.vaccine.2007.05.009 **Published:** AUG 10 2007

Times Cited: 30 (from Web of Science)

Cited References: 49 [[view related records](#)]  [Citation Map](#)

Abstract: CpG oligodeoxynucleotides (CpG ODN) are known to be a potent immunoadjuvant for a wide range of antigens. The aim of this study was to evaluate the role of CpG ODN co-encapsulated with rgp¹³ antigen in cationic liposomes (Lip-rgp¹³-CpG ODN) in immune response enhancement and protection in BALB/c mice against leishmaniasis. Lip-rgp¹³-CpG ODN prepared by using dehydration-rehydration vesicle (DRV) method significantly inhibited ($P < 0.001$) Leishmania major infection in mice measured by footpad swelling compared to Lip-rgp¹³, rgp¹³ alone, rgp¹³ plus CpG ODN, PBS or control liposomes. The mice immunized with Lip-rgp¹³-CpG ODN also showed the lowest spleen parasite burden, highest IgG_{2a}/IgG₁ ratio and IFN-gamma production and the lowest IL-4 production compared to the other groups. The results indicate that co-encapsulation of CpG ODN in liposomes improves the immunogenicity of Leishmania antigen. (c) 2007 Elsevier Ltd. All rights reserved.

Accession Number: WOS: 000248900800018

Document Type: Article

Language: English

Author Keywords: vaccine; liposome; rgp¹³; CpG ODN; Leishmaniasis; L. major

KeyWords Plus: CUTANEOUS LEISHMANIASIS; IMMUNOSTIMULATORY DNA; POTENT ADJUVANT; BACTERIAL-DNA; T-CELL; OLIGODEOXYNUCLEOTIDES; GP¹³; VACCINATION; ANTIGEN; VACCINES

Reprint Address: Jaafari, MR (reprint author), Mashhad Univ Med Sci, Sch Pharm, Biotechnol Res Ctr, Mashhad, Iran.

Addresses:

1. Mashhad Univ Med Sci, Sch Pharm, Biotechnol Res Ctr, Mashhad, Iran
2. Mashhad Univ Med Sci, Sch Pharm, Pharmaceut Res Ctr, Mashhad, Iran
3. Univ Tehran Med Sci, Ctr Res & Training Skin Dis & Leprosy, Tehran, Iran
4. Inst Pasteur, Biotechnol Res Ctr, Tehran, Iran
5. Univ British Columbia, Dept Med Genet, Vancouver, BC V2Z 1M1, Canada

E-mail Address: mahboudi@institute.pasteur.ac.ir

Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND

Web of Science Categories: Immunology; Medicine, Research & Experimental

Research Areas: Immunology; Research & Experimental Medicine

IDS Number: 202MM

ISSN: 0264-2810X